Objective: Ischemic stroke results in severe loss of neurological function and is a leading cause of death and disability in the world. Administration of a novel class of very long-chain polyunsaturated fatty acids (VLC-PUFAs) derivatives termed elovanoids (ELV34) or their VLC-PUFA precursor (FA34) has shown protective effects after uncompensated oxidative stress and ischemic stress. We found that ELV34 or FA34 delivery attenuates sensorimotor deficits after ischemic stroke. Using a single-cell multiome approach, we found a shift towards disease-associated glial phenotypes following ischemic stroke. Furthermore, ELV and its precursors protect against ischemic damage by restoring the pool of microglia, astrocytes, and oligodendrocytes towards a homeostatic cell-state. Methods: We used 10X Single Cell Multiome (ATAC + Gene Expression) to compare genomic and epigenomic responses in naïve rats and after experimental ischemic treatment. Adult Sprague-Dawley rats underwent 2 hours of middle cerebral artery occlusion (MCAo) via intraluminal suture. Rats received vehicle, ELV34, or FA34 delivered intranasally 1 hour, 1 day, and 2 days after 2 hours of MCAo. A composite neurological score was taken daily, and brains were harvested on day 3. Nuclei were isolated and processed according to the 10X Genomics Single Cell Multiome protocol. Results: ELV34 or FA34 treatment both reduced neurological deficits after MCAo. Joint RNA + ATAC single-cell analysis revealed that ELV34 or FA34 reduced the loss of neuronal populations and reduced infiltrating leukocytes after stroke. Sub-cluster analysis of microglia found that ELV34 and FA34 restored the pool of microglia expressing homeostatic markers (P2ry12, Tmem119, Selplg) while the primary microglia cluster in vehicle expressed disease-associated microglia markers (Spp1, Gpnmb, Cd63). Sub-cluster analysis in astrocytes, oligodendrocytes, and OPC revealed a similar shift in glial profiles towards a homeostatic state after ELV34 and FA34 treatment. Differential gene expression, pathway, and transcription factor motif analysis points to regulation of phagocytic clearance, anti-inflammatory signaling, and neurodegenerative pathways in glial cells after ELV34 or FA34 treatment. Conclusion: ELV34 and its precursor FA34 may exert their bioactivity by modulating conversion to neuroprotective cell phenotypes in ischemic stroke and other neurological diseases.
Ji et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: